Related Experiment Videos
[Gentamycin sulfate effectiveness and tolerance in patients with myelotoxic agranulocytosis]
Abstract:
Patients with myelotoxic agranulocytosis were treated with gentamicin administered intravenously as drop-wise infusions in a dose of 5 mg/kg body weight a day every 8 hours. The treatment course consisted of 7--24 days. No toxic reactions were observed. The therapeutic efficacy of gentamicin depended on the neutrophilic level and amounted to 50--60 per cent when the drug was used without identification of the causative agent. The prophylactic use of gentamicin decreased the infection incidence in patients with myelotoxic agranulocytosis, while the prophylactic efficacy of gentamicin was evident only when the number of the granulocytes was higher than 100/mm3 of the blood.
Insights
Gentamicin treatment for myelotoxic agranulocytosis showed no toxicity and 50-60% efficacy. Prophylactic use reduced infection incidence, particularly when granulocyte counts exceeded 100/mm3.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Myelotoxic agranulocytosis poses a significant risk of infection.
- Effective antibiotic strategies are crucial for managing patients with low granulocyte counts.
Purpose of the Study:
- To evaluate the therapeutic and prophylactic efficacy of gentamicin in patients with myelotoxic agranulocytosis.
- To assess the safety profile of gentamicin in this patient population.
Main Methods:
- Intravenous gentamicin administration at 5 mg/kg every 8 hours for 7-24 days.
- Observation of treatment outcomes, including therapeutic efficacy and infection incidence.
- Correlation of gentamicin efficacy with neutrophilic and granulocyte levels.
Main Results:
- No toxic reactions were observed during gentamicin treatment.
- Therapeutic efficacy ranged from 50-60% when the causative agent was unidentified.
- Prophylactic gentamicin decreased infection incidence, with significant efficacy when granulocyte counts were >100/mm3.
Conclusions:
- Gentamicin is a safe and potentially effective treatment for myelotoxic agranulocytosis.
- Prophylactic gentamicin can reduce infection rates in at-risk patients, contingent on baseline granulocyte levels.